Floatz logo

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE

Opioid Use

Wake Forest University Health SciencesSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Opioid Use cohort.

Asset / SponsorPhaseRating
METHADONE
Rutgers, The State University of New Jersey
Phase 4BBB
HYDROMORPHON
Endeavor Health
Phase 4BBB
FENTANYL
University of Crete
Phase 4BB
Bxcl501
Kaohsiung Veterans General Hospital.
Phase 4BB
LIDOCAINE
Tanta University
Phase 4BB

View all 28 →

Same molecule, other indications

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE is also rated in:

major depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
major depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →